2023 Tuberculosis Drug Discovery and Development Gordon Research Conference and Gordon Research Seminar

2023结核病药物发现与开发戈登研究大会暨戈登研究研讨会

• 批准号: 10675238
• 负责人: Dirk Schnappinger
• 金额: $ 0.6万
• 依托单位: GORDON RESEARCH CONFERENCES
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-07-11 至 2023-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10675238
• 关键词: Address; Architecture; Area; Automobile Driving; Bacterial Infections; Biology; Budgets; COVID-19; Cessation of life; Chemicals; Clinical; Clinical Trials; Clinical Trials Design; Collaborations; Communicable Diseases; Communities; Complex; Country; Coupled; Data; Development; Disclosure; Disease; Drug Combinations; Drug Industry; Drug resistance; Drug resistance in tuberculosis; Environment; Evaluation; Face; Faculty; Fostering; Funding Agency; Geography; Goals; Growth; Health Priorities; Hour; Human; Income; Industrialization; Infectious Agent; Injectable; Institution; International; Lead; Learning; Leisures; Location; Mentors; Methods; Multidrug-Resistant Tuberculosis; Mycobacterium tuberculosis; Oral; Participant; Performance; Pharmaceutical Preparations; Pharmacologic Substance; Play; Postdoctoral Fellow; Privatization; Regimen; Research; Research Personnel; Science; Scientist; Series; Site; Socialization; Spain; Speed; Structure; Students; Technology; Time; Training; Translational Research; Tuberculosis; Underrepresented Minority; United States National Institutes of Health; Woman; career; career development; design; drug development; drug discovery; drug efficacy; drug-sensitive; early-career faculty; fighting; global health; improved; innovation; insight; meetings; new technology; next generation; novel; novel strategies; novel therapeutics; pandemic disease; premature; prevent; programs; research study; side effect; success; symposium; tuberculosis chemotherapy; tuberculosis drugs; tuberculosis treatment

ABSTRACT This application seeks support for the 2023 Tuberculosis (TB) Drug Discovery & Development Gordon Research Conference (GRC) and Gordon Research Seminar (GRS) to be held in at the Rey Don Jaime Grand Hotel in Castelldefels, Spain from July 22-23 and July 23 – 28, 2023. This will be the eleventh GRC on TB Drug discovery (with the first being held in 2001 and thereafter on a biennial basis) and the fifth GRS associated with this GRC. For more than 20 years this conference series has held a unique place in the global portfolio of TB research conferences. For many years it has been oversubscribed, been rated above average by more than 70% of attendees and received a high-performance rating in the GRC Evaluation. Among the factors that makes this conference series stand out are its rigorous focus on TB drug development, the emphasis on presentation of unpublished data (enabled by the strictly enforced rules against recording or photographing of presentations), the disclosure of novel hit and lead compounds, the large fraction of attendees from the pharmaceutical industry, and the well-attended networking sessions. The overall theme for this GRC is “Leads, technologies and clinical trials for new TB drug regimens”. The conference will discuss and disclose recently developed lead molecules as well as new technologies and approaches to clinical trials, debate how recent insight into TB biology and performance of clinical drug combinations may facilitate identifying leads and improving regimens, review how new technologies and trial innovations can identify improved drug regimens, and discuss how to capitalize on successes in other disease areas. The focus of this conference is thus quite different from the most recent conference in this series, which centered around treatment shortening and was held in 2019. The GRC and associated GRS foster an environment wherein which researchers are encouraged to share cutting edge unpublished data and exchange ideas between both established and young investigators and trainees hereby promoting career development for all attendees. The GRC will include a “Power Hour”, an optional gathering for all meeting participants to address the challenges underrepresented minorities and women face in science and to support their professional growth. Both the GRC and the GRS programs will reflect the diversity of the scientists in the field with an aim of strong representation of women, underrepresented minorities, and international scientists. GRCs are unique in facilitating multiple opportunities for informal interactions between researchers from different sectors, geographies, and career stages, often resulting in exchanges leading to new collaborations. In this pandemic era, such opportunities have become rare and thus even more important to driving forward innovation in research.

摘要 本申请寻求对2023年结核病(TB)药物发现和开发Gordon Research的支持 会议(GRC)和戈登研究研讨会(GRS)将于#年在Rey Don Jaime Grand酒店举行 2023年7月22日至23日和7月23日至28日，西班牙卡斯特尔德费尔斯。这将是第11届关于结核病药物发现的GRC (第一次于2001年举行，此后每两年举行一次)和与该全球资源中心有关的第五次全球资源报告。 20多年来，这一系列会议在全球结核病研究组合中占有独特的地位 会议。多年来，它一直超额认购，超过70%的人的评级高于平均水平 并在GRC评估中获得了高性能评级。造成这一现象的因素包括 系列会议脱颖而出的是其对结核病药物开发的严谨关注，重点介绍了 未发布的数据(由严格执行的禁止记录或拍摄演示的规则启用)， 新的命中和先导化合物的披露，来自制药行业的大部分与会者， 以及上座率很高的网络会议。 GRC的总体主题是“新的结核病药物方案的领先地位、技术和临床试验”。这个 会议将讨论和披露最近开发的铅分子以及新技术和 临床试验的方法，讨论对结核病生物学和临床药物性能的最新见解 组合可能有助于确定线索和改进方案，审查新技术和试验如何 创新可以确定改进的药物方案，并讨论如何利用其他疾病的成功经验 区域。因此，本次会议的重点与本系列的最近一次会议有很大不同，后者 以缩短治疗为中心，于2019年举行。 GRC和相关的GR营造了一种鼓励研究人员分享的环境 尖端未发表的数据，并在老牌和年轻的调查人员和 学员在此促进所有与会者的职业发展。GRC将包括一个“动力小时”、一个 所有与会者参加会议的选择性聚会，以应对代表不足的少数群体和妇女面临的挑战 在科学上有面子，并支持他们的职业成长。GRC和GRS计划都将反映 该领域科学家的多样性，目标是女性代表人数较多，少数群体代表人数较少， 和国际科学家。GRC在促进非正式互动的多种机会方面是独一无二的 来自不同部门、不同地理位置和不同职业阶段的研究人员之间，经常进行交流 带来了新的合作。在这个大流行时代，这样的机会变得罕见，因此更是 对推动研究创新具有重要意义。